Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Shares Outstanding (2017 - 2025)

Catheter Precision (VTAK) has disclosed Shares Outstanding for 9 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding rose 806.38% to $1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 806.38% year-over-year, with the annual reading at $421296.0 for FY2024, 3228.82% up from the prior year.
  • Shares Outstanding for Q4 2025 was $1.7 million at Catheter Precision, up from $1.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $646.0 million in Q1 2022, with the low at $2229.0 in Q2 2025.
  • Average Shares Outstanding over 5 years is $43.4 million, with a median of $118000.0 recorded in 2021.
  • The sharpest move saw Shares Outstanding surged 993789.23% in 2022, then plummeted 99.92% in 2023.
  • Over 5 years, Shares Outstanding stood at $140190.0 in 2021, then soared by 360.09% to $645000.0 in 2022, then tumbled by 98.04% to $12656.0 in 2023, then skyrocketed by 3228.82% to $421296.0 in 2024, then soared by 290.96% to $1.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $1.6 million, $2229.0, and $421296.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.